ASCO 2019 – Kantar debates results from the KEYNOTE-062 trial
There were a number of debate-worthy outcomes from the KEYNOTE-062 trial that was presented at ASCO 2019 in Chicago yesterday.
The study looked at Merck & Co’s Keytruda as a first-line treatment for gastric cancer, and prompted questions about the meaningfulness of non-inferiority.
Kantar’s Debbie Warner and Michael Gaschler debate the results in the video below.
Click here to view exclusive live coverage from ASCO 2019.